OP-0580 Heterogeneous PSMA expression in prostate cancer: reason for negative Ga-68-PSMA PET/CT scan? Immunohistochemical validation of 40 surgical specimens [Abstract]
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: European Journal of Nuclear Medicine and Molecular Imaging, 48, S1, S. S206-S207
- Event
-
Veröffentlichung
- (where)
-
Augsburg
- (who)
-
Universität Augsburg
- (when)
-
2021
- Event
-
Veröffentlichung
- (where)
-
Berlin
- (who)
-
Springer
- (when)
-
2021
- Creator
-
Cytawa, W.
Kircher, S.
Seitz, A. K.
Weber, S.
Hartrampf, P.
Bandurski, T.
Lass, P.
Pokom, W.
Lapa, Constantin Frederik Victor
Buck, A. K.
- DOI
-
10.1007/s00259-021-05547-1
- URN
-
urn:nbn:de:bvb:384-opus4-919508
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cytawa, W.
- Kircher, S.
- Seitz, A. K.
- Weber, S.
- Hartrampf, P.
- Bandurski, T.
- Lass, P.
- Pokom, W.
- Lapa, Constantin Frederik Victor
- Buck, A. K.
- Universität Augsburg
- Springer
Time of origin
- 2021
Other Objects (12)
![Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens](/assets/placeholder/searchResultMediaUnknown.png)
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Pitfalls in PSMA imaging: [18F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
PSMA-Liganden PET/CT bei Patienten mit biochemischem Rezidiv nach radikaler Prostatektomie: Matched-Pair Vergleich von 68Ga-PSMA-11 und 18F-PSMA-1007
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Meta-analysis of 18 F-PSMA-1007 PET/CT, 18 F-FDG PET/CT, and 68Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
68Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
Standardized template for clinical reporting of PSMA PET/CT scans
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Pitfalls in PSMA imaging: [18F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
PSMA-Liganden PET/CT bei Patienten mit biochemischem Rezidiv nach radikaler Prostatektomie: Matched-Pair Vergleich von 68Ga-PSMA-11 und 18F-PSMA-1007
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Meta-analysis of 18 F-PSMA-1007 PET/CT, 18 F-FDG PET/CT, and 68Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
68Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
Standardized template for clinical reporting of PSMA PET/CT scans
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Pitfalls in PSMA imaging: [18F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
PSMA-Liganden PET/CT bei Patienten mit biochemischem Rezidiv nach radikaler Prostatektomie: Matched-Pair Vergleich von 68Ga-PSMA-11 und 18F-PSMA-1007
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Meta-analysis of 18 F-PSMA-1007 PET/CT, 18 F-FDG PET/CT, and 68Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
68Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
Standardized template for clinical reporting of PSMA PET/CT scans
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617